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“22q11 deletion syndrome” (22q11DS) is a rare genetic syndrome, in which most 
patients share the same deletion, but their clinical features may vary a great deal. The 
genetic mechanisms underlying the variable expressivity and reduced penetrance of 
22q11DS still have to be fully elucidated. Epilepsy has been reported in about 15.2% 
of the patients; however, few studies have focused on this topic, and in most cases, 
a detailed epileptic profile is missing. Since only a minority of patients experience epi-
leptic seizures, 22q11deletion can be considered a predisposing factor, which is not 
sufficient “per se” to cause epilepsy; to date, no candidate gene for epilepsy has been 
identified in the deleted region. We report on a 6-year-old girl with 22q11DS presenting 
a form of epilepsy that can be classified as “Panayiotopoulos syndrome.” Array CGH 
revealed an additional microduplication of 172 kb in 2q37, harboring three genes. One 
of these, DGKD (diacylglycerol kinase delta), is interrupted by the distal breakpoint of the 
duplication. DGKD encodes a cytoplasmic enzyme that phosphorylates diacylglycerol 
to produce phosphatidic acid. This is an important second messenger in a pathway 
of lipid signaling that has been implicated in epilepsy and other neurological diseases. 
Disruption of DGKD by a t(X;2) has been previously reported in a patient with epilepsy. 
The 2q37 microduplication was inherited from her mother, who never experienced 
epileptic seizures, thus this imbalance is not “per se” sufficient to cause epilepsy. It can 
be hypothesized that the epileptic phenotype is provoked by the simultaneous pres-
ence of 22q11.2 deletion and 2q37 duplication. It has been shown that rare additional 
copy-number variations (CNVs) outside the 22q11.2 region may modulate the risk of 
congenital heart defects. It is possible that also for the epileptic phenotype, the additional 
CNVs may represent an important modifying factor underlying the variable expressivity 
and incomplete penetrance in the 22q11DS.
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BaCKGRoUND
“22q11 deletion syndrome” (22q11DS) is a rare genetic syndrome 
with a reported prevalence of about 1:4,000 live births. Although 
most of the patients share exactly the same deletion of nearly 
3 Mb in 22q11.2, their clinical features may be highly variable 
ranging from a severe phenotype to a very mild one (1). The 
genetic mechanisms underlying the variable expressivity and 
reduced penetrance of 22q11DS still have to be fully elucidated.
Typical symptoms include multiple developmental anomalies 
such as congenital heart defects (CHD), palatal, renal, gastrointes-
tinal, ophthalmological, dental, and skeletal abnormalities as well 
as hypocalcemia, immunodeficiency, and endocrine dysfunction 
(1). Structural central nervous system (CNS) abnormalities, like 
polymicrogyria, cerebral atrophy, cerebellar hypoplasia, focal cor-
tical dysplasia, and subependymal heterotopia, are also reported 
(2). Neuropsychiatric (NP) manifestations such as neurodevelop-
ment disorders (developmental delay, cognitive impairment, and 
speech disturbances) and psychiatric disorders (attention deficit 
hyperactivity disorder, schizophrenia, and mood disorders) are 
often present (2–4).
Among the NP manifestations, seizures are conspicuous 
events, but in the majority of cases, they can be a secondary 
manifestation of other syndrome-associated features, such as 
hypocalcemia, hypoxia/ischemia secondary to CHD, and fever 
with recurrent infections. In the literature, the epileptic seizure 
incidence is estimated from about 10% (5) to 21% (6). In a recent 
article, the incidence of epilepsy in a cohort of 145 22q11DS 
children was reported to be 15.2%; excluding patients with “struc-
tural epilepsy” (CNS abnormalities), the prevalence of “genetic 
epilepsy” is 8.3% (2).
These findings suggest a link between “genetic epilepsy” and 
22q11DS, and this implies that the hemizygous deletion of one 
or more genes in this specific locus may be associated with 
epileptogenesis. However, 22q11.2 hemizygous deletion is not 
sufficient “per se” to cause epilepsy but constitutes a predispos-
ing genetic factor, since only a minority of patients experience 
epileptic seizures. It may be that a “second hit” is necessary to 
manifest the epileptic phenotype, but to date, the genetic mecha-
nisms that could increase the risk of epilepsy are not known.
Recently, array CGH has highlighted that humans are much 
more genetically variable than previously appreciated. To date, 
nearly 10–15% of the human genome has been annotated as har-
boring copy-number variations (CNVs), namely microdeletions 
and microduplications, ranging from 1 kb to several megabases 
(7). Their presence may contribute significantly toward human 
phenotypic variability, complex behavioral traits, and disease 
susceptibility.
Little is known about the contribution of additional CNVs 
on the phenotypic variability of 22q11DS. A recent article (8) 
focused on the role of rare CNVs as genetic modifiers predis-
posing to CHD in a very large cohort of patients with 22q11DS. 
When these CNVs were carefully examined for their gene con-
tent, specific cardiac networks appeared to be overrepresented in 
22q11DS CHD cases but not in 22q11DS controls with no cardiac 
phenotype, suggesting that CNVs outside the 22q11.2 region can 
modify the risk for CHD in 22q11DS.
We report on a 6-year-old girl with 22q11DS presenting a 
form of epilepsy that can be classified as “Panayiotopoulos syn-
drome” (PS). To the best of our knowledge, PS has never been 
associated with 22q11DS. Array CGH revealed a de novo typical 
22q11.2 microdeletion and a rare maternal microduplication of 
172 kb in 2q37, which could represent an important factor pre-
disposing to epilepsy. As in the case of CHD, additional CNVs 
outside the 22q11.2 region may modulate the risk of epileptic 
seizures in patients with 22q11DS.
Case RepoRt
The girl, the third child of healthy, unrelated parents, was born at 
full term after a normal pregnancy by cesarean section because 
of podalic presentation. Her mother had a previous miscarriage 
at 16  weeks of gestation. The neonatal course was regular. The 
patient came to our observation at 6 years of age because of recur-
rent episodes of vomiting. Her weight was 22.3 kg (−0.29 SD), 
height 118 cm (−0.61 SD), and BMI 16.6 (0.14 SD); she presented 
dysmorphic features such as a wide mouth with a “Cupid’s bow”-
shaped upper lip, epicanthic folds, prognathism and narrow 
biparietal diameter, and a II–III toe syndactyly.
Parents reported several autonomic partial seizures in sleep 
(ictal vomiting, retching, pallor, and nausea) sometimes associ-
ated with unilateral eye deviation and sometimes with secondary 
generalization (loss of consciousness and urine incontinence). 
The episodes started at the age of 4; on that first occasion, she 
seemed completely unresponsive and flaccid for about 30 min. 
After that, she began to have episodes of paroxysmal vomiting 
during the day and then during the night, the frequency of which 
increased, starting from one episode every 3  months to one 
episode per month.
The child had also recurrent otitis; the audiological evaluation 
showed mild bilateral transmission hypoacusis.
She has a mild developmental delay and an attention deficit 
hyperactivity disorder. At 6 years, a psychometric scale WISC-III 
(I.Q. tot: 75, V.I.Q.: 70, and P.I.Q.: 85) was administered, which 
highlighted lower limits of intellectual quality, with a significant 
discrepancy between verbal and performance skills, with dif-
ficulty in accepting, detaining, and recalling verbal information.
During hospital admission, blood chemical and amino acid 
examinations were performed, as well as brain MRI, cardiac, 
and abdominal Doppler sonography; all of these test results were 
normal. In particular, the blood proline value (192 μmol/L) was 
in the normal range (n.v. 117–332 μmol/L).
Awake electroencephalographic (EEG) showed occipital spikes 
during eye closure with generalized spike wave complex during 
sleep. Considering the clinical features and the EEG pattern, we 
diagnosed an occipital early onset epilepsy syndrome, PS.
In accordance to the literature data, we decided not to use any 
antiepileptic drug.
The child underwent an immunologic consultation. A general 
lymphocyte overview showed normal values comparing to age-
matched healthy controls; an extended evaluation of both T cell 
subpopulations by cytoflorimetric analysis showed that CD4+ 
and CD8+ effector memory (CD45RA−CD62L−) subset was 
abnormally high in the first examination.
FiGURe 1 | (a) Array CGH profile of chromosome 22. Array CGH of the proband showing chromosome 22 on the left and the 22q11.2 deletion highlighted on the 
right. (B) Array CGH profile of chromosome 2. Array CGH of the proband showing chromosome 2 on the left and the 2q37 duplication highlighted on the right.
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An auxological and endocrinological consultation showed 
vitamin D deficiency and normal blood calcium levels (about 
10 mg/dL, n.v. 8.6–10.2). The child did not assume supplements 
or other medications.
After written informed consent, a 180K oligo-array (Agilent, 
Santa Clara, CA, USA) was performed, according to standard 
procedures; the analysis was made with the Agilent dedicated 
software (Cytogenomics, Agilent). The Database of Genomic 
Variants (DGV) was used to define the variants found. Array 
CGH tests were also performed on her parents.
Array CGH detected in the proband a de novo ~2.6 Mb dele-
tion in 22q11.2, from position 18,894,835 to position 21,464,119 
(hg19 map) and an additional 172 kb duplication in 2q37.1, from 
position 234,191,549 to position 234,363,450 (Figures  1A,B). 
taBle 1 | Description of the functional role of the genes co-expressed with DGKD.
Gene official name ReFseQ iD Function
PRODH Proline dehydrogenase 1 *606810 This gene encodes a mitochondrial protein that catalyzes the first step in proline degradation. 
Mutations in this gene are associated with hyperprolinemia type 1 and susceptibility to 
schizophrenia 4 (SCZD4)
HIRA Histone cell cycle regulation  
defective, Saccharomyces cerevisiae, 
homolog of, A
*600237 This gene encodes a histone chaperone that preferentially places the variant histone H3.3 in 
nucleosomes. This gene plays an important role in the formation of the senescence-associated 
heterochromatin foci. These foci likely mediate the irreversible cell cycle changes that occur in 
senescent cells. Insufficient production of the gene may disrupt normal embryonic development
C22orf29 Chromosome 22 open reading frame 29 Not characterized
ARVCF Armadillo repeat gene deleted in 
velocardiofacial syndrome
*602269 ARVCF is a member of the catenin family. This family plays an important role in the formation of 
adherens junction complexes, which are thought to facilitate communication between the inside 
and outside environments of a cell
MED15 Mediator complex subunit 15 *607372 MED15 (PCQAP) is a component of the activator-recruited cofactor complex or the metazoan 
Mediator complex and is essential for TGFB/Activin/Nodal/Smad2/3 signal transduction
LZTR1 Leucine zipper-like transcriptional  
regulator 1
*600574 The LZTR1 gene encodes a protein that belongs to a functionally diverse superfamily of BTB/
POZ (broad complex, tramtrack and bric-a-brac/poxvirus, and zinc finger) proteins. BTB-
containing proteins control fundamental cellular processes, ranging from the regulation of 
chromatin conformation to the cell cycle
GNB1L G protein subunit beta 1 like *610778 This gene encodes a G-protein beta-subunit-like polypeptide, which is a member of the WD 
repeat protein family. Members of this family are involved in a variety of cellular processes, 
including cell cycle progression, signal transduction, apoptosis, and gene regulation
FiGURe 2 | interactions between DGKD and the genes located in 
22q11.2, as shown by GeNeMania. DGKD shows a co-expression with 
seven genes in 22q11.2 (PRODH, HIRA, GNB1L, C22orf29, ARVCF, MED15, 
and LZTR1) (pink lines) and functionally interacts with GNB1L (green line).
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FISH with a commercial probe (Cytocell, Tarrytown, NY, USA) 
was used to confirm the 22q11.2 deletion in the proband.
The 2q37.1 duplication was inherited from her healthy mother 
who did not present any neurological disease except for recurrent 
headaches.
Putative interaction networks among genes harbored in the 
22q11.2 and in the 2q37.1 region were built by the GeneMANIA1 
with default parameters. Physical, co-expression, and pathway 
gene–gene interactions were evaluated (9). As shown in Figure 2, 
the network revealed that DGKD is co-expressed with PRODH, 
HIRA, GNB1L, C22orf29, ARVCF, MED15, and LZTR1 and that 
it interacts with GNB1L. Details about the functional role of these 
genes are reported in Table 1.
1 http://www.genemania.org/.
DisCUssioN
We report on a 6-year-old girl with 22q11DS presenting prolonged 
autonomic seizures (nausea, retching, ictal vomiting, pallor, and 
urine incontinence) that fits the criteria of PS.
Epilepsy is reported in 22q11DS, but few studies have 
focused on this topic, and most of them do not address epilepsy 
phenotype in more detail. In a recent article (5), a careful 
revision of the literature on 22q11DS patients with epilepsy 
and the description of six new cases have been made; among 
the 53 individuals reported in PubMed, 47% were diagnosed 
with focal epilepsy (including cases of Rolandic and atypical 
absence epilepsy), 41% had the diagnosis of genetic generalized 
epilepsy (including cases with myoclonic features and juvenile 
myoclonic epilepsy), 6% had myoclonic jerks and unspecified 
epilepsy, and 6% had unspecified epilepsy without myoclonic 
features. To the best of our knowledge, PS has never been 
associated with 22q11DS.
Epilepsy of the proband can be defined as “genetic” since nei-
ther structural CNS abnormalities nor metabolic conditions pre-
disposing to epilepsy were found. In 22q11DS, “genetic epilepsy” 
has a prevalence of about 8.3%, suggesting that one or more genes 
in this specific locus may be associated to epileptogenesis (2).
This case shows the typical deletion between the low-copy 
repeats A and D in 22q11.2, where about 50 RefSeq genes are 
harbored. Neither ion channel genes nor genes whose hemizy-
gous deletion causes epilepsy have been identified. The only 
gene that can be associated with epilepsy is PRODH (Proline 
Dehydrogenase 1), whose homozygous deletion causes type I 
hyperprolinemia, characterized by a high proline level in blood 
and various NP symptoms, including epileptic seizures (10). In 
this proband, PRODH has a functional allele since her proline 
level was normal.
5Bertini et al. 22q11DS and a 2q37 Duplication
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However, it is worth noting that some other genes in the 
22q11 deletion are involved in brain function and development, 
like SNAP29 (synaptosomal-associated protein 29) and RTN4R 
(reticulon four receptor, NOGO RECEPTOR) (11, 12). A third 
gene, DGCR8 (microprocessor complex subunit 8), encodes 
a subunit of the miRNA microprocessor complex and has a 
genome-wide effect on the biogenesis of micro-RNAs, which are 
particularly expressed in the mammalian brain (13). Therefore, 
it is possible that the hemizygous expression of multiple genes 
involved in the development of neuronal circuits can explain the 
broad spectrum of structural abnormalities and the coexistence 
of several NP manifestations, including epilepsy.
Since only a minority of patients experience epileptic seizures, 
the hemizygous deletion of 22q11 is not sufficient “per se” to cause 
epilepsy, and a “second hit” is necessary. In the present case, in 
addition to the 22q11 deletion, the array CGH data showed a 
172-kb duplication in 2q37.1, where three genes are harbored: 
ATG16L1 (Autophagy 16-like 1), SAG (S-antigen; retina and 
pineal gland), and DGKD (diacylglycerol kinase delta).
Several evidences support a role of DGKD in epileptogenesis.
DGKD encodes a cytoplasmic enzyme that phosphorylates 
diacylglycerol (DAG) to produce phosphatidic acid (PA). Both 
DAG and PA are important second messengers in a pathway of 
lipid signaling that has been implicated in epilepsy and other 
neurological diseases. Of special interest, in this respect, is 
DAG-gated transient receptor potential cation channels (e.g., 
TRPC3, -6, and -7), in which DAG binding directly opens the 
channels (14).
In Drosophila and mice, expression studies support a role for 
DGKD in development and function of CNS; EEG assessment of 
Dgkd knockdown mice revealed abnormal epileptic discharges in 
half of the mutant mice evaluated (15).
In humans, disruption of the DGKD sequence by a transloca-
tion between a chromosome X and a chromosome 2 has been 
previously reported in a patient with epilepsy (14).
Further data about human DGKD haploinsufficiency have 
been searched for in two publically available databases that collect 
pathogenetic imbalances in Decipher,2 ClinVar,3 and HGMD,4 a 
database that collects human genome mutations. This search did 
not give additional information, since the cases with only one 
imbalance involving DGKD (9 deletions and 4 duplications in 
Decipher, 7 deletions and 12 duplications in ClinVar) have a very 
large extent with an average size of several megabases, and their 
clinical description is very limited. No point mutations in DGKD 
are present in HGMD.
As for the 22q11.2 deletion, the 2q37.1 duplication, which 
leads to DGKD haploinsufficiency, is not “per  se” sufficient to 
cause epilepsy. In the proband, this duplication is inherited from 
her mother, who never experienced epileptic seizures; a case 
with a duplication breaking DGKD sequence is reported in the 
DGV5 that collects CNVs identified in healthy controls (16).
2 https://decipher.sanger.ac.uk/.
3 https://www.ncbi.nlm.nih.gov/clinvar/.
4 http://www.hgmd.org.
5 http://dgv.tcag.ca/.
We have searched for epistatic interactions between genes 
harbored in the two imbalances. DGKD shows a co-expression 
with six genes located in 22q11.2 (PRODH, HIRA, C22orf29, 
ARVCF, MED15, and LZTR1), and it functionally interacts 
with GNB1L, a gene involved in cell cycle progression, sig-
nal transduction, apoptosis, and gene regulation (Figure  2; 
Table 1).
Even if we cannot exclude that other smaller genetic variants 
or mutations elsewhere in the genome may play a role, it is likely 
that in this case the 2q37.1 duplication, which leads to DGKD 
haploinsufficiency, may represent the “second hit” necessary for 
the outcome of the epileptic phenotype.
As in the case of CHD, additional rare CNVs outside the 
22q11.2 region may represent an important modifying factor 
underlying the variable expressivity and incomplete penetrance 
of epileptic seizures in 22q11DS.
CoNClUDiNG ReMaRKs
Association between 22q11DS and epilepsy is evident; thus, 
a detailed description of the epileptic phenotype, when pre-
sent, is mandatory. In larger cohorts of patients, an accurate 
analysis of the additional rare CNV gene content will be useful 
to elucidate the genetic mechanisms underlying the pathological 
phenotype.
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